The modification at the heart of the study is deceptively simple. Lysine is one of the twenty amino acids that make up proteins, and when a small acetyl group is attached to its side chain, the physics of the protein changes. Acetylation can neutralize a positive charge, alter how the protein folds, reshape the surfaces it uses to bind partners, change how long it survives in circulation, and modulate its enzymatic activity. Because a single protein can carry acetyl groups at many different lysine positions, each with potentially distinct consequences, the modification multiplies the functional diversity of the proteome many times over. In cells and tissues, lysine acetylation is famous as a regulator of gene expression and metabolism; in blood plasma, the protein-rich, cell-free fraction of blood, it has been far less systematically explored, particularly in the context of neurodegenerative disease.

To capture this hidden layer, the researchers turned to mass spectrometry, the workhorse technology of modern proteomics. In this approach, proteins extracted from plasma are broken into short peptide fragments, which are then separated by liquid chromatography and fired into a mass spectrometer. The instrument fragments each peptide further and records the resulting spectra, from which the identity of the parent protein and the exact position of any chemical modification can be inferred. Crucially, the team enriched specifically for acetylated peptides before analysis, a step that is essential because acetylated peptides are typically rare amid the overwhelming abundance of unmodified material in plasma. Without such enrichment, the signal from these modified peptides would drown in noise.

The scale of the resulting dataset is what sets the study apart. From plasma samples obtained from twenty Alzheimer’s disease patients and twenty age-matched controls, the researchers acquired more than 7,600 independent tandem mass spectrometry spectral measurements corresponding to 350 unique lysine acetylation sites. Each of those sites represents a specific lysine residue on a specific plasma protein where an acetyl group was detected and localized. This is not merely a catalog of proteins present in blood, which earlier plasma proteomics efforts have assembled in depth, but a map of where on each protein the chemical decoration occurs, in a clinical context where such information did not previously exist.

The study is, according to its authors, the first lysine acetylation-directed proteomic landscape of Alzheimer’s-related human plasma samples. That first matters because plasma is where blood-based diagnostics for Alzheimer’s are increasingly being developed. Current leading biomarkers, such as measures of phosphorylated tau in plasma, focus on a different post-translational modification, phosphorylation, and on proteins that originate in the brain. Acetylation offers a complementary view: it reports on the state of the abundant plasma proteome itself, including lipoproteins, complement factors, coagulation proteins and carriers that mediate inflammation, lipid transport and immune signaling, all of which are increasingly implicated in Alzheimer’s pathogenesis through large-scale genetic and epidemiological studies.

Among the proteins carrying acetylation marks, apolipoproteins stand out as a biologically plausible focus. These lipid-binding proteins shuttle cholesterol and other fats through the bloodstream, and the strongest genetic risk factor for late-onset Alzheimer’s disease, the APOE gene, encodes an apolipoprotein. The study’s abbreviation list also flags low-density lipoprotein, the cholesterol-carrying particles whose biology intersects with both cardiovascular and neurodegenerative disease, suggesting that acetylation states on lipid transport machinery were among the features captured in the dataset. How acetylation alters the function of these carriers, and whether specific acetylation patterns track with disease status, are questions the dataset now makes answerable.

Perhaps the most unexpected dimension of the work lies beyond canonical proteins altogether. The mass spectrometry measurements detected acetylated peptide sequences that do not map to the standard catalog of human proteins. Instead, they correspond to short open reading frames, stretches of the genome that ribosome profiling technologies have shown are actively translated into tiny peptides even though they were long dismissed as non-coding. The idea that such non-canonical peptides circulate in plasma, and that they carry lysine acetylation marks detectable by mass spectrometry, expands the searchable space of blood-borne molecules. It hints that the plasma proteome is even less fully inventoried than assumed, and that some disease-relevant signals may reside in proteins that standard annotation pipelines ignore.

Methodologically, the study reflects the demanding craft of plasma proteomics. The authors employed filter-aided sample preparation, a technique that uses molecular-weight filters to clean and digest protein samples, and combined complementary fragmentation methods, collision-induced dissociation and higher-energy collisional dissociation, to maximize the information extracted from each peptide. Quantification was performed label-free, comparing spectral intensities across samples rather than relying on chemical tags introduced beforehand. The abbreviation NSRP1, for nuclear speckle splicing regulatory protein 1, appears in the study’s key terms, indicating that even proteins not normally thought of as plasma residents contributed identifiable acetylated peptides to the landscape.

The study design itself was deliberately controlled. Twenty patients with Alzheimer’s disease and twenty age-matched controls provide a matched comparison in which age, the strongest demographic risk factor, is held constant. The plasma samples were obtained from a commercial vendor operating under applicable regulations for the collection and handling of biological specimens, which the authors note meant separate ethics approval was not required. The work was funded by a Grant-in-Aid for Transformative Research Areas from Japan’s Ministry of Education, Culture, Sports, Science and Technology, with additional research funding from Abbott Laboratories, and one co-author is an employee of Abbott Japan, a disclosure the authors make explicitly in the paper.

What the study does not yet claim is a diagnostic test. A landscape of 350 acetylation sites across forty individuals is a foundation, not a finished clinical instrument. Validating any individual acetylation site as a biomarker will require larger and more diverse cohorts, longitudinal sampling, and confirmation that the modification patterns are reproducible across laboratories and platforms. The authors frame their contribution accordingly: as a resource that may contribute to a more extensive understanding of the biochemical properties of human plasma protein components in relation to Alzheimer’s disease pathogenesis. In a field racing toward blood-based early detection, the message of the study is that the blood itself still holds layers of information, written in chemical tags, that science is only now learning to read.

Subject of Research: Lysine acetylation profiling of plasma proteins in Alzheimer's disease using mass spectrometry

Article Title: Lysine acetylation-directed high-resolution plasma proteomic landscape of Alzheimer’s disease

Article References: Kozuka-Hata, H., Kitamura, A., Hiroki, T., Miyamura, N., Yoshimura, T., Tsumoto, K., & Oyama, M. (2026). Lysine acetylation-directed high-resolution plasma proteomic landscape of Alzheimer’s disease. Clinical Proteomics. https://doi.org/10.1186/s12014-026-09635-y

Image Credits: AI Generated

DOI: 10.1186/s12014-026-09635-y

Keywords: Alzheimer's disease, plasma proteomics, lysine acetylation, mass spectrometry, post-translational modification, apolipoprotein, short open reading frame, biomarkers, Clinical Proteomics, blood-based diagnostics, Lysine, acetylation-directed

Platelets have long been dismissed as simple clotting agents, fragments of megakaryocytes whose job is to plug wounds. Over the past decade, however, they have been recast as sophisticated sentinels of disease. Tumors educate platelets: they release vascular endothelial growth factor and other pro-angiogenic signals, shield circulating tumor cells from immune attack, and swap molecular information with the tumor microenvironment. Because platelets internalize and process RNA from the conditions they encounter, their transcriptome acts as a circulating diary of systemic illness. The new study, published in Cancer Reports, revisits publicly available platelet RNA-sequencing data from 84 treatment-naive glioblastoma patients and 319 healthy controls, refining the original cohort by excluding astrocytoma grade IV cases to match the WHO 2021 definition of glioblastoma as an IDH-wildtype grade 4 diffuse astrocytic tumor, and removing a small batch of control samples affected by a technical artifact.

The analytical design is what makes the study interesting to computational biologists. Rather than relying on a single method, the team ran two deliberately different approaches on the same dataset of 4,412 expressed genes. The first, Gene Set Enrichment Analysis, or GSEA, ignores arbitrary significance cutoffs and instead ranks the entire transcriptome, asking whether known biological pathways shift in a coordinated way between patients and controls. The second, threshold-based differential expression analysis followed by Elastic Net regularization, is a machine learning workflow: DESeq2 first narrows thousands of genes to 323 candidates with fold changes above 1.3 and a false discovery rate below 0.1, and then a penalized logistic regression model shrinks most coefficients to zero, retaining only the most informative predictors. The result was a compact 103-gene signature that distinguishes glioblastoma from healthy blood with striking accuracy.

That accuracy is the headline number. Evaluated on an independent test set kept completely separate during model development, the 103-gene platelet signature achieved an area under the curve of 0.99 with a misclassification rate of just five percent. Across ten random repetitions of the entire procedure, the mean AUC held at 0.989, with mean sensitivity of 0.877 and specificity of 0.980. Crucially, the team did not stop there. They compared their signature against 100 randomly generated 103-gene panels, and while random genes also performed surprisingly well in this high-dimensional setting, the real signature consistently outperformed the random reference distribution in both AUC and balanced accuracy. In an additional external platelet RNA cohort, without any genome-wide feature selection, the signature still achieved an AUC of 0.93, evidence that the signal is at least partly transferable across laboratories and sequencing pipelines.

The GSEA arm of the study tells a different, more mechanistic story. Positively enriched pathways in patients clustered around core platelet biology: blood coagulation, platelet activation, wound healing, vascular and circulatory processes, cytoskeletal organization, and extracellular matrix remodeling. To tame the redundancy inherent in Gene Ontology terms, the researchers applied a Markov clustering framework, grouping the enriched terms into 22 clusters that spanned vascular processes, RNA processing, ribosomal function, immune regulation, autophagy, and cellular metabolism. Because GSEA results can depend on the random seed, the entire enrichment analysis was repeated ten times with different seeds, and the top pathways proved highly consistent across iterations. Notably, transcripts associated with ribosomal function and protein synthesis were downregulated in patient platelets, echoing earlier reports of suppressed translation-related programs in tumor-educated platelets.

Perhaps the most puzzling finding was the enrichment of bacterial response pathways in the predictive gene signature, given that none of the patients showed signs of infection when their blood was drawn. The authors propose a plausible explanation rooted in damage-associated molecular patterns, or DAMPs. Necrotic cells deep inside glioblastoma release these molecules, which activate Toll-like receptors on platelets and effectively mimic the molecular alarm signals that bacteria trigger. In other words, a tumor that never hosted an infection can still make the platelet transcriptome look as if one were raging. This sterile-inflammation mechanism could help explain the chronic inflammatory tone that glioblastoma cultivates systemically, and it fits with the description of tumors as wounds that refuse to heal, perpetually regenerating tissue that recruits myeloid cells, fuels angiogenesis, and remodels the extracellular matrix.

The predictive genes themselves sketch a portrait of immune and cellular dysfunction. Elevated transcripts included B2M and LGALS2, both implicated in immune evasion, while downregulated genes such as CXCR2P1 and OAS1 hint at blunted anti-tumor interferon responses. Genes tied to proliferation, including CAMK2D and PIK3IP1, to metabolism, including MAOB and FKBP5, and to epigenetic regulation, such as the chromatin factor CBX7, round out the panel. The authors are careful to stress a critical caveat: Elastic Net selects genes for predictive power, not proven mechanism, and the Gene Ontology analysis of the 103-gene panel yielded no terms surviving multiple-testing correction, so the functional annotations attached to the signature are explicitly descriptive rather than definitive evidence of pathway overrepresentation.

To test whether the strongest platelet signals reflect anything real about the tumor microenvironment, the team turned to independent glioma datasets. In bulk RNA data spanning multiple glioma grades, platelet activation and aggregation signatures correlated strongly with wound healing signatures, and wound healing programs were elevated in glioma patients compared with normal controls. Single-cell RNA sequencing data analyzed with a pseudobulk approach confirmed the pattern on two different platforms, 10x Genomics and SMART-Seq, with the correlation between platelet activation and wound healing scores appearing even stronger in the SMART-Seq samples. Because high-quality external platelet RNA cohorts remain scarce, this cross-dataset triangulation is supportive rather than a direct replication, but it suggests that the platelet transcriptome is genuinely tracking tumor-associated biology rather than laboratory noise.

The study is candid about its limits. The cohort, though large by platelet RNA standards, still contains a modest number of glioblastoma cases; the thresholds used for gene selection are conventional rather than biologically derived; and clinical annotation was too incomplete to rule out confounding by medications or other conditions that also reprogram platelets. Many platelet activation signatures are shared across cancers and inflammatory diseases, so the findings cannot be treated as glioblastoma-specific without further validation, and pathway annotations curated from nucleated cells must be interpreted cautiously when applied to anucleate platelets. Even so, the work demonstrates that a routine blood draw, read through the right computational lens, can reveal coordinated systemic responses to one of medicine’s most formidable tumors, and it lays a concrete foundation for larger, fully annotated studies that could one day turn tumor-educated platelets into a non-invasive diagnostic and monitoring tool for brain cancer.

Subject of Research: Platelet-derived RNA biomarkers for glioblastoma detection

Article Title: Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis

Article References: Giczewska, A., Pastuszak, K., van Hout, L., Post, E., Ramaker, J., Zwaan, K., Supernat, A., & Westerman, B. A. (2026). Deepening the Understanding of Platelet‐Derived RNA as Biomarker for Glioblastoma Through GSEA , TDEA , and Elastic Net Regularization Analysis. Cancer Reports, 9(10), Article e70656. https://doi.org/10.1002/cnr2.70656

Image Credits: AI Generated

DOI: 10.1002/cnr2.70656

Keywords: glioblastoma, platelet RNA, tumor-educated platelets, liquid biopsy, GSEA, Elastic Net, biomarker, RNA sequencing, tumor microenvironment, DAMPs, machine learning, blood-based diagnostics